(Reuters) – The U.S. Food and Drug Administration (FDA) on Friday approved Bristol-Myers Squibb’s cell-based gene therapy, Breyanzi, to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or have relapsed after, at least two other types of systemic treatment.
The FDA granted approval of Breyanzi for the treatment of the cancer that starts in white blood cells to Bristol-Myers Squibb’s unit Juno Therapeutics Inc.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Aditya Soni)
